Novartis swoops in to bag Selexys and its sickle cell drug in $665M deal
Whatever Oklahoma City-based Selexys Pharmaceuticals just saw in its newly-wrapped Phase II study for sickle cell disease, the data must have been impressive. Pharma giant Novartis has stepped in and closed the loop on its 2012 buyout option, bagging the company in a deal valued at up to $665 million.
The object of Novartis’s desire is SelG1, an anti-P-selectin antibody designed to slash the number of vaso-occlusive pain crises patients with sickle cell disease suffer. Investigators will release the details on the mid-stage data at ASH in early December.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
